Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LN-145 |
Synonyms | |
Therapy Description |
LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LN-145 | LN145 | LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06566092 | Phase I | Lifileucel LN-145 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Recruiting | USA | 0 |
NCT04111510 | Phase II | LN-145 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT04614103 | Phase II | LN-145 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Recruiting | USA | NLD | DEU | CHE | CAN | 0 |
NCT03108495 | Phase II | LN-145 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | 0 |
NCT03083873 | Phase II | LN-145 | Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | Completed | USA | 0 |
NCT03645928 | Phase II | Lifileucel + Pembrolizumab LN-145 LN-145 + Pembrolizumab | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Recruiting | USA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | 0 |
NCT03419559 | Phase II | LN-145 Durvalumab + LN-145 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |